Clinical Trial

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Study acronym: STEEL
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
Protocol Amendment History 46 amendments
This ClinicalTrials.gov record has been amended 46 times since 2019-01-16; most recent amendment 2025-12-08.
Status change: Recruiting → Active, Not Recruiting 2023-06-01
Status change: Not Yet Recruiting → Recruiting 2019-06-05
Trial Details
NCT Number NCT03809000
Lead Sponsor RTOG Foundation, Inc.
Collaborators: Pfizer, Astellas Pharma Inc
Conditions Prostate Cancer
Enrollment 188 participants
Start Date 2019-04-15
Primary Completion 2023-04-07 (estimated)
Study Completion 2029-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-30